EPISODE · Sep 10, 2014 · 15 MIN
Podcast 174: PARADIGM and Heart Failure
from Clinical Conversations · host NEJM Group
The PARADIGM-HF trial of LCZ696 — a novel compound that both blocks the renin-angiotensin system with an ARB component and blocks neprilysin’s degradation of natriuretic peptides — increased survival in heart failure by some 20% relative to enalapril. It seems to be a big deal, and the trial’s two principal authors have agreed to talk about their work and its larger meaning. Running time: 15 minutes Other links: The study in the New England Journal of Medicine (free) NEJM Journal Watch coverage of the study (free) The post Podcast 174: PARADIGM and Heart Failure first appeared on Clinical Conversations.
Embed this episode
What this episode covers
The PARADIGM-HF trial of LCZ696 — a novel compound that both blocks the renin-angiotensin system with an ARB component and blocks neprilysin’s degradation of natriuretic peptides — increased survival in heart failure by some 20% relative to enalapril. It seems to be a big deal, and the trial’s two principal authors have agreed to talk […]
NOW PLAYING
Podcast 174: PARADIGM and Heart Failure
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.